R
Restorbio
Innovative medicines targeting aging biology to prevent or treat age-related diseases
About Restorbio
resTORbio is a biopharmaceutical company focused on developing innovative medicines that target the biology of aging to prevent or treat age-related diseases. The company operates in the healthcare and pharmaceutical market, primarily serving older adults who are at risk of or suffering from chronic diseases associated with aging. resTORbio's business model revolves around the discovery, development, and commercialization of drugs that modulate specific biochemical pathways, such as the TORC1 pathway, which are believed to regulate aging and its related diseases. The company generates revenue through the development and sale of these therapeutic drugs, as well as through partnerships and collaborations with other pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 57.0/100
- Industry
- Health, Jobs Recruitment
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Risk Management, Biotechnology, Biotech and Pharma, Silver Economy, Hard Tech, elderly care, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Nov 2017 | $40M | $160M | Rock Springs Capital · OrbiMed · Quan Capital · Nest.Bio Labs | — |
| SERIES AOther financing | Jan 2017 | $25M | $100M | PureTech | — |
Growth signals
Latest recorded traffic for Restorbio is 340 monthly website visits, down 49.3% over the last three months. Restorbio's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
ReViralAntiviral therapeutics targeting respiratory syncytial virus (RSV) |
Stevenage, United Kingdom | Acquired | 5 | $121M | $525M |
Bio Green Med SolutionClinical-stage biopharma developing cell cycle cancer therapies |
Berkeley Heights, United States | Operational | |||
CircadiaContactless patient monitoring system for predictive healthcare |
London, United Kingdom | Operational | |||
| Rochester, United States | Acquired | ||||
InnoVeinInnoVein is revolutionizing vein care with an implantable valve |
San Carlos, United States | Closed | |||
Ambio HealthWireless health and activity monitoring solutions especially for chronic patients and the elderly |
Stamford, United States | Operational | |||
HealthsenseHealthsense | Remote Monitoring Services |
Mendota Heights, United States | Operational | |||
VoCarePersonal care and safety products that help elderly and chronically ill patients |
Indianapolis, United States | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Restorbio in the Boston ecosystem
The Restorbio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
PureTech
Rock Springs Capital
OrbiMed
Quan Capital
Nest.Bio LabsRecharge Capital
Source: Dealroom Talent Intelligence.
Global footprint
See Restorbio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








